Optimizing Cimzia in Crohn's Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

certolizumab pegol

certolizumab pegol 200 mg every 2 weeks

BIOLOGICAL

certolizumab pegol

certolizumab pegol 400 mg every 2 weeks

BIOLOGICAL

certolizumab pegol

certolizumab pegol 400 mg every 4 weeks

BIOLOGICAL

certolizumab pegol

certolizumab pegol 400 mg every 2 weeks

Trial Locations (1)

30342

RECRUITING

Atlanta Gastroenterology Associates, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Atlanta Gastroenterology Associates

OTHER

NCT01024647 - Optimizing Cimzia in Crohn's Patients | Biotech Hunter | Biotech Hunter